AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue
- 31 December 1996
- journal article
- clinical trial
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 50 (5) , 220-227
- https://doi.org/10.1016/0753-3322(96)87662-1
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV DiseaseAnnals of Internal Medicine, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS?Biomedicine & Pharmacotherapy, 1994
- A screening model of anti-HIV non AZT cross resistance virostaticsBiomedicine & Pharmacotherapy, 1993
- The in vivo effect of ellipticine analogues on the blood concentration of Friend virus: a murine model for studying anti-HIV drugsBiomedicine & Pharmacotherapy, 1993
- Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivativeNucleic Acids Research, 1991
- The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) InfectionAnnals of Internal Medicine, 1990
- Amino acridines action on Friend's retrovirus in relation to their molecular ionizationBiomedicine & Pharmacotherapy, 1989
- DNA topoisomerases as potential targets of antiviral actionPharmacology & Therapeutics, 1989
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987